Article Versions Notes

Galdopórpora JM, Martinena C, Bernabeu E, Riedel J, Palmas L, Castangia I, Manca ML, Garcés M, Lázaro-Martinez J, Salgueiro MJ, et al. Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy. Pharmaceutics. 2022; 14(5):959. https://doi.org/10.3390/pharmaceutics14050959

Galdopórpora, Juan M., Camila Martinena, Ezequiel Bernabeu, Jennifer Riedel, Lucia Palmas, Ines Castangia, Maria Letizia Manca, Mariana Garcés, Juan Lázaro-Martinez, Maria Jimena Salgueiro, and et al. 2022. "Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy" Pharmaceutics 14, no. 5: 959. https://doi.org/10.3390/pharmaceutics14050959

Galdopórpora, J. M., Martinena, C., Bernabeu, E., Riedel, J., Palmas, L., Castangia, I., Manca, M. L., Garcés, M., Lázaro-Martinez, J., Salgueiro, M. J., Evelson, P., Tateosian, N. L., Chiappetta, D. A., & Moretton, M. A. (2022). Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy. Pharmaceutics, 14(5), 959. https://doi.org/10.3390/pharmaceutics14050959